Pathfinder Cell Therapy Gross Profit

Pathfinder Cell Therapy (PFND) currently reports a gross profit of $0 as of September 2015. That compares with $-13K in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Pathfinder Cell Therapy's gross profit history and peer comparisons.

Pathfinder Cell Therapy's gross profit increased from $-13K to $0 — a 100.0% year-over-year increase (period ending September 2015). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pathfinder Cell Therapy's gross profit of $0 is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Pathfinder Cell Therapy reported $0 in gross profit as of September 2015. That compares with $-13K in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Pathfinder Cell Therapy, and consider following PFND for alerts when major investors trade the stock.